WALTHAM, Mass. - Thermo Fisher Scientific Inc. (NYSE: TMO), a prominent player in the Life Sciences Tools & Services industry with a market capitalization of $163 billion, has announced plans to invest $2 billion in its U.S. operations over the next four years. The investment aims to enhance the country’s life sciences sector and bolster economic competitiveness. According to InvestingPro data, the company’s stock is currently trading near its 52-week low of $410, suggesting potential value opportunity for investors.
The investment will include $1.5 billion in capital expenditures to improve and expand manufacturing operations across the United States, complemented by an additional $500 million in research and development (R&D) focusing on high-impact innovation.
Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific, expressed the company’s confidence in America’s continued global leadership in science and innovation. Casper emphasized the importance of developing and producing life-saving medicines and therapies within the United States.
Thermo Fisher, known as a major manufacturer of medicines, operates 64 manufacturing sites in 37 states, employing more than 50,000 U.S. workers. The company’s growth has been notable, with revenues doubling since 2017 from $21 billion to $43 billion. It currently invests $1 billion annually in R&D in the U.S. and this new investment is expected to create high-paying jobs and add to the company’s manufacturing and lab services capacity.
The company’s commitment is seen as a move to support a resilient U.S. healthcare supply chain and is anticipated to have a significant multiplier effect on the American economy.
Thermo Fisher’s role as a global leader in serving science includes providing a wide array of products and services that support life sciences research, laboratory productivity, patient health, and the development and manufacture of therapies.
The information provided in this article is based on a press release statement from Thermo Fisher Scientific Inc.
In other recent news, Thermo Fisher Scientific Inc. reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $5.15, against a forecast of $5.11. The company’s revenue reached $10.36 billion, slightly above the anticipated $10.23 billion. Additionally, Thermo Fisher announced a definitive agreement to acquire Solventum’s purification and filtration business for $4.1 billion, marking a significant expansion move. The company also updated its 2025 revenue guidance to a range of $43.3 billion to $44.2 billion, with an adjusted EPS guidance of $21.76 to $22.84. In terms of analyst activity, there was no mention of upgrades or downgrades. Thermo Fisher is also investing $2 billion in U.S. manufacturing and R&D over the next four years as part of its strategic initiatives. These developments highlight Thermo Fisher’s ongoing efforts to maintain its market position and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.